Glenmark books Rs 283.875 crore Humana litigation charge

Glenmark Pharmaceuticals Limited accrued a Rs 283.875 crore consolidated exceptional item for the period ended 30 September 2026, including its US subsidiary’s $15 million settlement with Humana, Inc. and related legal, regulatory and other one-time costs. Glenmark said the settlement involved no admission of liability or illegality.

What did Glenmark record for the Humana settlement?

Glenmark recorded a Rs 283.875 crore exceptional item in its consolidated results for the period ended 30 September 2026. The charge followed a settlement entered during the quarter ended 30 September 2026 by Glenmark Pharmaceuticals Inc., USA, a subsidiary, with Humana for $15 million.

The Rs 283.875 crore disclosed is not identified as the rupee value of the Humana settlement alone. Glenmark said the amount comprises the Humana settlement, underlying legal costs, one-time regulatory costs and other costs accrued for the period ended 30 September 2026. The filing gives no separate rupee allocation for those components.

Glenmark classified the combined charge as an exceptional item. Its consolidated cash-flow statement shows exceptional-item loss of Rs 283.875 crore for the half year ended 30 September 2026, compared with Rs 1,708.348 crore in the corresponding half year ended 30 September 2025.

What allegations are involved in Glenmark’s US cases?

Glenmark said it and its subsidiary were named in multiple antitrust and consumer-protection lawsuits, including class actions consolidated in the US District Court for the Eastern District of Pennsylvania. The cases concern industry-wide allegations of price-fixing, market allocation and related anticompetitive conduct in generic drugs.

The plaintiffs listed in the filing include putative classes of direct purchasers, end payers and indirect purchasers of generic drugs, as well as numerous private direct-action plaintiffs. Glenmark said litigation with other parties continues, meaning the Humana settlement does not conclude all of the disclosed proceedings.

Glenmark stated that the Humana settlement makes clear it denies every allegation against it. It also said the agreement was not based on Glenmark having considered or admitted liability or illegality. The filing presents the $15 million agreement as a settlement rather than a court finding against Glenmark.

How does this charge compare with earlier litigation provisions?

Glenmark’s Rs 283.875 crore current-period exceptional item was Rs 1,424.473 crore lower than the Rs 1,708.348 crore recognised in the half year ended 30 September 2025. The periods are not component-for-component comparable because the earlier period included litigation provisions and other non-recurring items, while the current amount combines the Humana settlement with legal, regulatory and other costs.

For the quarter ended 30 June 2025, Glenmark provided Rs 323.232 crore for an estimated $37.75 million settlement with a putative direct-purchaser class. That settlement was subject to approval by the court overseeing the litigation, and Glenmark said it denied the allegations and did not admit liability or illegality.

The 31 March 2026 disclosure also listed a Rs 278.070 crore provision relating to a settlement with the state attorney general, alongside the Rs 323.232 crore direct-purchaser provision. Glenmark said both were charged as exceptional items and that litigation continued with other parties, placing the September 2026 charge within a sequence of disclosed litigation-related costs.

How did the exceptional item affect Glenmark’s half-year cash flow?

Glenmark reported consolidated profit before tax from operations of Rs 981.677 crore for the half year ended 30 September 2026, down from Rs 1,062.979 crore a year earlier. In the cash-flow reconciliation, it added back the Rs 283.875 crore exceptional-item loss in arriving at operating profit before working-capital changes.

Consolidated operating cash flow was an outflow of Rs 203.318 crore in the 2026 half year, compared with an inflow of Rs 2,835.567 crore in the corresponding 2025 period. Net changes in operating assets and liabilities were an outflow of Rs 1,800.124 crore, including changes in trade receivables of Rs 567.619 crore, inventories of Rs 297.201 crore, and trade payables and other liabilities of Rs 420.229 crore.

Financing activities generated Rs 601.947 crore in the 2026 half year, versus an outflow of Rs 1,490.424 crore a year earlier. Glenmark reported net short-term borrowing proceeds of Rs 858.680 crore, compared with net repayment of Rs 1,335.076 crore in the prior-year period, while cash and cash equivalents closed at Rs 1,289.929 crore on 30 September 2026.

What remains unresolved in Glenmark’s US litigation?

Glenmark said matters remain under litigation with other parties despite the Humana settlement and the previously disclosed arrangements with the direct-purchaser class and state attorney general. The filing does not give a timetable for resolution of remaining claims or quantify potential further settlement, legal or regulatory costs.

Glenmark’s earlier disclosure said its direct-purchaser settlement was subject to court approval. The September 2026 note does not state an equivalent approval condition for the Humana settlement, but it confirms that the broader litigation has not ended as of 30 September 2026.

The filing also describes the Humana amount as part of a wider Rs 283.875 crore accrual that includes underlying legal and one-time regulatory costs. That accounting treatment identifies a cost for the reporting period, while leaving unquantified the financial effect of unresolved cases involving other plaintiffs.

Conclusion

The filing shows a lower consolidated exceptional-item loss in the September 2026 half year than a year earlier, but it also records another US litigation-related settlement and associated costs. Glenmark continues to deny the allegations, and the disclosed settlement does not represent an admission of liability or illegality.

The next disclosed issue to watch is the progress of litigation involving other parties. Court approval remains relevant to the previously disclosed direct-purchaser settlement, while any subsequent settlement, ruling or reassessment of legal and regulatory costs could affect exceptional items in a future reporting period.